— Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses – confirmed in a representative tumor biopsy – all within two weeks of initial treatment…

Halifax, Nova Scotia–(Newsfile Corp. – October 17, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon EDT to discuss…

Halifax, Nova Scotia–(Newsfile Corp. – August 25, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology,…

Halifax, Nova Scotia–(Newsfile Corp. – July 23, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology,…

Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients Halifax, Nova Scotia–(Newsfile Corp. – July 7, 2025) –  Sona Nanotech Inc. (CSE:…